Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer

Oncogenic KRAS-mutant lung cancers remain treatment refractory. A better understanding of the immune response of KRAS-mutant lung cancers is required to facilitate the development of potential therapeutic strategies. Regulatory T cells (Tregs) are a subset of immune cells that promote tumor progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byung-Seok, Clinton, Jelita, Wang, Qing, Chang, Seon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959450/
https://www.ncbi.nlm.nih.gov/pubmed/32002289
http://dx.doi.org/10.1080/2162402X.2019.1682380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959450/
https://www.ncbi.nlm.nih.gov/pubmed/32002289
http://dx.doi.org/10.1080/2162402X.2019.1682380

Ejemplares similares